4/A: Matinas BioPharma Holdings: Robert Eide Reports Changes in Beneficial Ownership

Robert Eide, a director of Matinas BioPharma Holdings, reports changes in beneficial ownership including transactions involving Series C Convertible Preferred Stock and warrants.

Summary

• Robert J. Eide, a director of Matinas BioPharma Holdings, filed an amendment to a previous Form 4, reporting changes in his beneficial ownership of the company's securities.
• The reported transactions include the acquisition of Series C Convertible Preferred Stock and warrants by Pembroke & Partners, where Eide serves as the managing partner.
• Pembroke purchased 984 shares of Series C Convertible Preferred Stock and 3,358,364 warrants for $984,000.
• Eide directly holds 750 shares of common stock and indirectly holds another 750 shares as the managing member of Isagen LLC.
• Pembroke's voting power is capped at 23% of the outstanding common stock, with limits on the shares issuable upon conversion of preferred stock (9.99%) and exercise of warrants (4.99%).

Sentiment

Score: 6

Explanation: The document is a standard regulatory filing, so the sentiment is neutral. It reflects routine transactions and ownership changes.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance.

Industry Context

This filing is a routine disclosure related to changes in beneficial ownership, which is common in the biopharmaceutical industry, especially when companies raise capital through private placements involving convertible securities and warrants.

Comparison to Industry Standards

• Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, as mandated by the SEC.
• The structure of the securities purchase agreement, involving preferred stock and warrants, is a common method for financing in the biotech industry, similar to deals seen with companies like BioCryst Pharmaceuticals or Amarin Corporation.
• The voting power cap of 23% and the limits on share issuance upon conversion and exercise are typical provisions to prevent hostile takeovers and maintain shareholder control, aligning with practices observed in similar transactions involving small-cap biotech firms.

Stakeholder Impact

• The transaction could potentially impact shareholders by diluting existing equity if the preferred stock is converted and warrants are exercised.
• The investment by Pembroke & Partners could be viewed positively as a sign of confidence in the company's prospects.

Key Dates

Keywords

beneficial ownership, Form 4, Matinas BioPharma Holdings, MTNB, Robert Eide, Series C Convertible Preferred Stock, warrants, Pembroke & Partners, securities